High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab
Article in Ophthalmology and Therapy (August 2024)
The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.
Article in Ophthalmology and Therapy (August 2024)
Article in Ophthalmology and Therapy (August 2024)
Article in Journal of Clinical Medicine (July 2024)